Loading...
OTCM
SNPHY
Market cap3.37bUSD
Dec 05, Last price  
9.96USD
1D
0.20%
1Q
-8.62%
Jan 2017
-18.56%
Name

Santen Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
OTCM:SNPHY chart
P/E
14.43
P/S
1.74
EPS
107.24
Div Yield, %
—
Shrs. gr., 5y
-2.66%
Rev. gr., 5y
4.43%
Revenues
300.00b
-0.65%
98,397,000,000100,485,000,000103,394,000,000101,618,000,000110,594,000,000110,812,000,000114,416,000,000119,066,000,000148,663,000,000161,831,000,000195,291,000,000199,096,000,000224,942,000,000234,026,000,000241,555,000,000249,605,000,000266,257,000,000279,037,000,000301,965,000,000300,004,000,000
Net income
36.25b
+36.05%
13,022,000,00013,147,000,00012,650,000,00010,123,000,00018,722,000,00021,333,000,00017,160,000,00016,520,000,00017,109,000,00024,032,000,00053,373,000,00023,054,000,00035,261,000,00031,943,000,00023,618,000,0006,830,000,00027,218,000,000-14,948,000,00026,642,000,00036,247,000,000
CFO
60.93b
-16.13%
20,878,000,00014,959,000,00015,468,000,00011,849,000,00026,110,000,00017,769,000,00021,483,000,0009,942,000,00025,958,000,00025,386,000,00022,525,000,00010,843,000,00042,843,000,00032,894,000,00039,947,000,00038,808,000,00046,043,000,00037,147,000,00072,649,000,00060,928,000,000
Dividend
Sep 28, 20230.076365 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.
URL
https://www.santen.co.jp/ja/
IPO date
Nov 04, 1963
Employees
4,144
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT